Value of biotargeted drugs in airway mucus therapy of asthma
10.12092/j.issn.1009-2501.2024.04.009
- Author:
Duo MOU
1
;
Kexin LIU
1
;
Chun CHANG
1
;
Kexin LIU
2
Author Information
1. Department of Respiratory and Critical Care Medicine, Peking University Third Hospital
2. Department of Respiratory and Critical Care Medicine, Wuhan First Hospital
- Publication Type:Journal Article
- Keywords:
airway mucus;
asthma;
biotargeted drugs
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(4):423-426
- CountryChina
- Language:Chinese
-
Abstract:
Airway mucus plug is a common phenotype in asthma that increases the risk of acute asthma attacks by causing aggravation of airflow obstruction. Given its important role in asthma, treatment targeting airway mucus plugs may be a strategy to control asthma progression and prevent fatal asthma exacerbations. Previous studies have shown that acidosophils and T2 type inflammation are related with the formation of mucus plugs, and biotargeted drugs targeting the above pathways may be effective in the treatment of airway mucus plugs.
